other material
confidence high
sentiment positive
materiality 0.65
TransCode Phase 1a TTX-MC138 trial meets safety endpoint; 64% stable disease at 6 months
Transcode Therapeutics, Inc.
- 16 patients received 86 doses; median treatment 11.3 weeks (range 4-52.4 weeks).
- No dose-limiting toxicities; recommended Phase 2a dose set at 4.8 mg/kg.
- 9 of 14 evaluable patients (64%) achieved stable disease lasting ≥6 months.
- Three patients remain on study (at 21, 16, and 14 cycles); one thyroid cancer patient had dramatic thyroglobulin drop.
- Phase 2a trial initiated in ctDNA-positive colorectal cancer after curative-intent therapy.